5 Stocks Pushing The Diversified Services Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 49 points (0.3%) at 16,147 as of Friday, Nov. 29, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,869 issues advancing vs. 987 declining with 109 unchanged.

The Diversified Services industry currently sits up 0.4% versus the S&P 500, which is up 0.3%. A company within the industry that fell today was Net 1 Ueps Technologies ( UEPS), up 29.0%. Top gainers within the industry include KBR ( KBR), up 1.8%, R.R. Donnelley & Sons Company ( RRD), up 1.6% and Priceline.com ( PCLN), up 0.7%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Qiagen ( QGEN) is one of the companies pushing the Diversified Services industry lower today. As of noon trading, Qiagen is down $0.20 (-0.8%) to $23.40 on light volume. Thus far, 135,380 shares of Qiagen exchanged hands as compared to its average daily volume of 731,000 shares. The stock has ranged in price between $23.39-$23.59 after having opened the day at $23.48 as compared to the previous trading day's close of $23.60.

QIAGEN N.V., through its subsidiaries, provides sample and assay technologies worldwide. Qiagen has a market cap of $5.5 billion and is part of the services sector. The company has a P/E ratio of 43.7, above the S&P 500 P/E ratio of 17.7. Shares are up 30.0% year to date as of the close of trading on Wednesday. Currently there are 3 analysts that rate Qiagen a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Qiagen as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, revenue growth, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Qiagen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Verisk Analytics ( VRSK) is down $0.41 (-0.6%) to $65.04 on light volume. Thus far, 191,169 shares of Verisk Analytics exchanged hands as compared to its average daily volume of 780,400 shares. The stock has ranged in price between $64.83-$65.64 after having opened the day at $65.51 as compared to the previous trading day's close of $65.45.

Verisk Analytics, Inc. provides proprietary data, analytics methods, and embedded decision support solutions for detecting fraud in property and casualty (P&C) insurance, financial, and healthcare industries primarily in the United States. Verisk Analytics has a market cap of $11.0 billion and is part of the services sector. The company has a P/E ratio of 31.3, above the S&P 500 P/E ratio of 17.7. Shares are up 28.4% year to date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Verisk Analytics a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Verisk Analytics as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, revenue growth, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Verisk Analytics Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Fiserv ( FISV) is down $0.65 (-0.6%) to $110.10 on light volume. Thus far, 175,765 shares of Fiserv exchanged hands as compared to its average daily volume of 473,700 shares. The stock has ranged in price between $110.00-$111.12 after having opened the day at $110.27 as compared to the previous trading day's close of $110.75.

Fiserv, Inc., together with its subsidiaries, provides financial services technology worldwide. Fiserv has a market cap of $14.3 billion and is part of the services sector. The company has a P/E ratio of 25.1, above the S&P 500 P/E ratio of 17.7. Shares are up 40.1% year to date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Fiserv a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Fiserv as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Fiserv Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Myriad Genetics ( MYGN) is down $0.72 (-2.4%) to $29.93 on light volume. Thus far, 448,080 shares of Myriad Genetics exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $29.59-$30.61 after having opened the day at $30.32 as compared to the previous trading day's close of $30.65.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. Myriad Genetics has a market cap of $2.3 billion and is part of the services sector. The company has a P/E ratio of 14.7, below the S&P 500 P/E ratio of 17.7. Shares are up 12.5% year to date as of the close of trading on Wednesday. Currently there are 5 analysts that rate Myriad Genetics a buy, 2 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Myriad Genetics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Myriad Genetics Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Ulta Salon Cosmetics & Fragrances ( ULTA) is down $0.78 (-0.6%) to $127.69 on light volume. Thus far, 208,717 shares of Ulta Salon Cosmetics & Fragrances exchanged hands as compared to its average daily volume of 701,200 shares. The stock has ranged in price between $126.43-$128.75 after having opened the day at $128.66 as compared to the previous trading day's close of $128.47.

Ulta Salon, Cosmetics & Fragrance, Inc. operates specialty retail stores in the United States. Its stores offer cosmetics, fragrance, haircare, and skincare products, as well as related accessories and services. Ulta Salon Cosmetics & Fragrances has a market cap of $8.2 billion and is part of the services sector. The company has a P/E ratio of 43.7, above the S&P 500 P/E ratio of 17.7. Shares are up 30.7% year to date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Ulta Salon Cosmetics & Fragrances a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Ulta Salon Cosmetics & Fragrances as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Ulta Salon Cosmetics & Fragrances Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the diversified services industry could consider iShares Dow Jones US Cons Services ( IYC) while those bearish on the diversified services industry could consider ProShares Ultra Short Consumer Sers ( SCC).
null

If you liked this article you might like

Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen

Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen

What IBM's Genomic Partnership With Quest Says About Thermo Fisher, Diagnostics Peers

What IBM's Genomic Partnership With Quest Says About Thermo Fisher, Diagnostics Peers

3 Diversified Services Stocks Nudging The Industry Higher

3 Diversified Services Stocks Nudging The Industry Higher

Qiagen (QGEN) Stock Soars as Q2 Results Surpass Expectations

Qiagen (QGEN) Stock Soars as Q2 Results Surpass Expectations

Watch Out: Barbarians At The Gate For Qiagen (QGEN)

Watch Out: Barbarians At The Gate For Qiagen (QGEN)